WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "7bb06b80-a1db-4846-a44b-47d5b2d1c96a"}, "_deposit": {"created_by": 3, "id": "14192", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "14192"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00014192", "sets": ["1134"]}, "author_link": ["362", "24339", "24333", "20454", "24335", "24338", "24334", "361", "24336", "24337", "329", "24332", "97"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-01-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "8398", "bibliographicPageStart": "8389", "bibliographicVolumeNumber": "7", "bibliographic_titles": [{"bibliographic_title": "Oncotarget"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 \u003c 320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Impact Journals LLC"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.18632/oncotarget.6690", "subitem_relation_type_select": "DOI"}}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1949-2553", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Izumi, Kouji"}], "nameIdentifiers": [{"nameIdentifier": "362", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80646787", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=80646787"}, {"nameIdentifier": "80646787", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000080646787"}]}, {"creatorNames": [{"creatorName": "Mizokami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "97", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050248580"}]}, {"creatorNames": [{"creatorName": "Lin, Hsiu-Ping"}], "nameIdentifiers": [{"nameIdentifier": "24332", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ho, Hui-Min"}], "nameIdentifiers": [{"nameIdentifier": "24333", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwamoto, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "24334", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maolake, Aerken"}], "nameIdentifiers": [{"nameIdentifier": "24335", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Natsagdorj, Ariunbold"}], "nameIdentifiers": [{"nameIdentifier": "24336", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitagawa, Yasuhide"}], "nameIdentifiers": [{"nameIdentifier": "361", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00452102", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000000452102"}]}, {"creatorNames": [{"creatorName": "Kadono, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "329", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=10397218"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000010397218"}]}, {"creatorNames": [{"creatorName": "Miyamoto, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "24337", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Huang, Chiung-Kuei"}], "nameIdentifiers": [{"nameIdentifier": "24338", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Namiki, Mikio"}], "nameIdentifiers": [{"nameIdentifier": "20454", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=70155985"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000070155985"}]}, {"creatorNames": [{"creatorName": "Lin, Wen-Jye"}], "nameIdentifiers": [{"nameIdentifier": "24339", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-IZUMI-K-8389.pdf", "filesize": [{"value": "2.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2000000.0, "url": {"label": "ME-PR-IZUMI-K-8389.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/14192/files/ME-PR-IZUMI-K-8389.pdf"}, "version_id": "7aadd80c-7e78-4d68-b16f-686364a57495"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Androgen deprivation therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Biomarker", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CCl2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Risk classification", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer"}]}, "item_type_id": "4", "owner": "3", "path": ["1134"], "permalink_uri": "http://hdl.handle.net/2297/44860", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "14192", "relation": {}, "relation_version_is_last": true, "title": ["Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer"], "weko_shared_id": -1}
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
http://hdl.handle.net/2297/44860
http://hdl.handle.net/2297/44860b6aa4fbe-f06c-4751-b6ef-e6200c87591f
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-IZUMI-K-8389.pdf (2.0 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Izumi, Kouji
× Izumi, Kouji× Mizokami, Atsushi× Lin, Hsiu-Ping× Ho, Hui-Min× Iwamoto, Hiroaki× Maolake, Aerken× Natsagdorj, Ariunbold× Kitagawa, Yasuhide× Kadono, Yoshifumi× Miyamoto, Hiroshi× Huang, Chiung-Kuei× Namiki, Mikio× Lin, Wen-Jye |
|||||
書誌情報 |
Oncotarget 巻 7, 号 7, p. 8389-8398, 発行日 2016-01-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1949-2553 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.18632/oncotarget.6690 | |||||
出版者 | ||||||
出版者 | Impact Journals LLC | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 < 320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |